Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 18/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | ROS1 | P08922 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | CD63 | P08962 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422466 | 0.88 | BTK (0.55) | BTK | |
| SCHEMBL1422805 | 0.85 | JAK2 (0.53) | JAK2 | |
| SCHEMBL1422569 | 0.85 | BTK (0.56) | BTK | |
| SCHEMBL13626485 | 0.82 | SYK (0.47) | SYKBTKJAK2NTRK1ROS1 | |
| SCHEMBL1422735 | 0.80 | BTK (0.52) | BTKJAK2 | |
| SCHEMBL1422631 | 0.79 | BTK (0.47) | BTK | |
| SCHEMBL1784132 | 0.79 | BTK (0.59) | BTK | |
| SCHEMBL1422629 | 0.79 | BTK (0.44) | BTK | |
| SCHEMBL1422622 | 0.77 | BTK (0.38) | BTKAURKA | |
| SCHEMBL1422552 | 0.77 | BTK (0.56) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | claimed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | claimed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | claimed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | claimed |
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426424-B2 | Certain substituted amides, method of making, and method of use thereof | CGI PHARMACEUTICALS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | CGI PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2297105-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2009137596-A1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118233-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | SYK 2/4885BTK 1/4885JAK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.